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Abstract
It has long been known that the salivary glands of hematophagous (blood-feeding) arthropods secrete soluble apyrases,
which are potent nucleotide hydrolyzing enzymes capable of hydrolyzing extracellular ATP and ADP, the latter being a
major agonist contributing to platelet aggregation. Only recently, however, has the identification of proteins homologous
to these apyrases been reported in non-blood-feeding organisms such as rodents and humans. In this review, we present an
overview of the diverse family of apyrases first described in the blood-feeding arthropods, including the identification and
characterization of the soluble and membrane-bound vertebrate enzymes homologous to these arthropod apyrases. We
also describe the enzymatic properties and nucleotide specificities of the expressed enzymes, and insights gained into the
structure and function of this calcium activated nucleotidase (CAN) family from biophysical, mutagenesis and
crystallography studies. The potential therapeutic value of these proteins is also discussed.
Abbreviations: ADP– adenosine diphosphate; CAN–calcium activated nucleotidase; EST–expressed sequence tag;
GDP–guanosine diphosphate; NCR–nucleotidase conserved region; NTPDase–nucleoside triphosphate diphosphohydro-
lase; SCAN–soluble calcium activated nucleotidase
Overview of the Fsoluble_ apyrase family
Hemostasis (the prevention of blood loss) is a vertebrate
process with three main components: The plasma protein
clotting factor cascade; vasoconstriction; and platelet
aggregation. To facilitate feeding, hematophagus (blood-
feeding) arthropods such as fleas [1], ticks [2], biting
midges [3], and sand flies [4, 5] have evolved mechanisms
to disarm all three components and thereby inhibit hemo-
stasis in their hosts. Contained within the saliva of such
blood-feeding organisms are a variety of potent bioactive
compounds, including anticoagulants, vasodilators, and
antiplatelet factors. For recent reviews on the antihemo-
static strategies of blood-feeding arthropods, see [6Y8].
We are particularly interested in one mechanism utilized
by these blood-feeding organisms to inhibit hemostasis:
The injection of soluble salivary apyrases (ATP and ADP
hydrolyzing enzymes, EC 3.6.1.5) at the site of host skin
puncture. These apyrases are members of a family of
calcium-dependent proteins that rapidly hydrolyze extra-
cellular nucleotides such as adenosine tri- and diphosphate
[9]. Lacerations produced by the arthropod’s mouth parts
whilst probing for a blood vessel in the host likely expose
platelets to copious amounts of extracellular ADP, which is
released from injured cells and from the dense granules of
activated platelets. ADP represents one of the most
important physiological agonists for platelet recruitment,
aggregation and plug formation via activation of platelet
purinergic receptors (recently reviewed in [10Y13]), and
the apyrases facilitate the bloodYmeal acquisition for these
organisms by inhibiting the ADP-mediated activation of
host platelets through an increase in ADP catabolism [8].
Although these soluble apyrases were initially described
in the saliva of several different types of blood-feeding
arthropods, the cloning of the Cimex lectularius (bedbug)
apyrase resulted in the identification of homologous
proteins in non-blood-feeding vertebrates (human and
mouse) [9]. Although only identified through deduced
amino acid sequences in the GenBank expressed sequence
tags (ESTs) database, with no protein expression data to
support their presumed apyrase activity, that report
established the potential existence of proteins in non-
blood-feeding vertebrates that are clearly related to the
salivary apyrases found in blood-feeding invertebrates.
Subsequent to that report, two studies describing the
identificationofverysimilar cDNAs from the blood-feeding
arthropods Lutzomyia longipalpis (sandfly) and Phleboto-
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showed the similarity in enzymatic function between the
three blood-feeding arthropod enzymes, and pointed out
additional putative apyrases in Caenorhabditis elegans and
Drosophila melanogaster based on sequence homologies.
The amino acid sequences of these putative Ca
2+-depen-
dent apyrases are conserved among arthropods and verte-
brates (e.g., bedbug and human apyrases show 45% overall
amino acid identity) and appear to have diverged from a
common ancestral enzyme [9] (see Figure 1). Whether
these vertebrate sequences encoded true apyrases with
similar enzymatic properties and physiological functions
however, would not be known until later.
Cloning, expression and enzymatic characterization
of the vertebrate homologues of the arthropod
salivary apyrases
Failer et al. [14] cloned the rat homologue of the soluble
bed bug apyrase, characterized the enzymatic activity, and
studied the cellular distribution after expression in CHO
cells. Their results demonstrate that, similar to the
arthropod apyrases, the enzyme was strictly dependent
upon calcium (maximum activity seen at 1 mM calcium),
with no activity in the presence of magnesium. Unlike the
soluble blood-feeding arthropod apyrases however, the
hydrolysis of ADP was not detectable for the expressed
rat enzyme, although it is not clear if this was due to
limitations in the sensitivity of the detection assay. The
rank order of nucleotide hydrolysis for the rat apyrase
was found to be UDP 9 GDP = IDP \ CDP, with little
hydrolysis of nucleoside triphosphates, and no detectable
hydrolysis of nucleoside monophosphates. In addition, no
soluble or secreted form was detected in the conditioned
media of transfected CHO cells, unlike the soluble versions
described for the arthropods. Lastly, Northern blot analyses
showed expression in all rat tissues examined, and
immunolocalization studies revealed that the enzyme was
preferentially localized to the endoplasmic reticulum of
transfected cells, presumably playing a role in nucleotide
sugar/nucleoside monophosphate exchange. Thus, unlike
the soluble ADP and ATP hydrolyzing apyrases found in
the blood-feeding arthropods, whose primary function is
presumably to serve as an anti-hemostatic agent, the
substrate preference and subcellular localization of the rat
calcium activated nucleotidase suggest a very different
function in the rat, likely involving intracellular glycosyl-
ation reactions [14]. (We use the acronym "CAN" for
"Calcium Activated Nucleotidase", as the name for this
enzyme family, in keeping with the new gene nomencla-
ture proposed for these proteins at http://www.ncbi.nlm.
nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&
dopt=Graphics&list_uids=124583).
Further analysis of multiple sequence alignments of
vertebrate and invertebrate family members by Failer et al.
[14] revealed eight conserved clusters of amino acids
presumably important for structure and enzymatic activity.
No relatedness was found to the eNTPDase nucleotidase
family of enzymes and their unique Fapyrase conserved
regions_ [15]. Consistent with their subcellular localization
studies, the presence of an extended amino-terminus and
RXR endoplasmic reticulum retention/retrieval motif was
found in all three vertebrate sequences examined (rat,
mouse, and human, see Figure 2). The rat N-terminal
sequence is predicted to be a hydrophobic sequence that
allows retention in the cellular membranes of transfected
CHO cells. The authors concluded that N-terminal se-
quence shortening and signal peptide cleavage may be a
specific evolutionary adaptation of the blood-feeding
arthropod apyrases. It should be noted that the prediction
as to whether or not there is a signal peptide cleavage site
in these proteins (using the FSignalP_ program at the
ExPASy (Expert Protein Analysis System) website: http://
us.expasy.org/) depends on the assumed start of the amino
acid sequences, which depends on which of the multiple
possible start codons/initiation methionines are presumed
to initiate translation, which, in most cases, is unknown.
The same year that the characterization of the rat homo-
logue was reported, Smith et al. described the cloning and
expression of the human homologue of the bed bug apyrase
(first referred to as SCAN-1, for soluble calcium activated
nucleotidase-1 [16]). When expressed in COS-1 cells,
Figure 1. Phylogenetic analysis of the human calcium activated
nucleotidase and related family members. The human protein sequence,
along with the 10 other most closely related sequences, were aligned using
the computer program CLUSTALW, and phylogenetic distances were
determined and presented graphically by the Phylip Drawtree program,
available through the Biology Workbench of the San Diego Supercom-
puter Center at http://workbench.sdsc.edu/. The lengths of the lines
connecting the proteins are proportional to the phylogenetic distances
between the sequences. The GenBank accession numbers of the proteins
in this work are given in parentheses: Human (Homo sapiens)
(AAM94564), Mus musculus (AAH20003), Rattus norvegicus
(NP_653355), Drosophila melanogaster (AAF54638), Cimex lectularius
(AAD09177), Phlebotomus papatasi (AAG17637), Lutzomyia longipalpis
(AAD33513), Anopheles gambiae (CAC35453), Xenopus laevis
(AAH41215), Bos taurus (XP_596269), Gallus gallus (XP_427661).
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including the strict requirement for calcium for activity, a
pH optimum around 7, and a nucleotide preference of
UDP 9 GDP 99 ADP, with no detectable hydrolysis of
nucleoside monophosphates. Unlike the expressed rat
enzyme however, which was shown to be membrane-
bound [14], the human enzyme that was characterized was
a soluble protein found in the conditioned media of trans-
fected cells, likely produced by cleavage at the predicted
signal peptide cleavage site (see Figure 2)[ 16].
Further enzymatic characterization of the human nucle-
otidase was performed by Murphy et al. [17]. Those
investigators expressed the soluble portion of the human
enzyme in E. coli, and refolded the enzyme from the
resultant bacterial inclusion bodies. The bacterially
expressed human apyrase was similar in enzymatic
properties to the mammalian cell produced soluble form,
indicating that a transmembrane domain and post-transla-
tional modifications that do not occur in bacteria (such as
glycosylation) are not necessary for proper folding of the
protein or nucleotidase activity. Many divalent cation
chloride salts were tested (CaCl2, MgCl2, MnCl2, SrCl2,
CuCl2, CoCl2, and NiCl2), but only calcium was able to
support nucleotide hydrolysis. Interestingly, those authors
also found that the human protein was a calcium-binding
protein (as detected by changes in protein absorbance,
fluorescence, and activity as a function of calcium con-
centration) with a calcium-triggered transition from an
enzymatically inactive to an active form with half-
saturation at about 90 mM CaCl2 at low ionic strength [17].
Another important characteristic of the human calcium-
activated nucleotidase that distinguishes it from other
unrelated nucleotidases such as the naturally occurring
soluble forms of human NTPDases (i.e., NTPDase5 and
NTPDase6) is its remarkable stability. For example,
Valenzuela et al. [5] reported that the P. papatasi apyrase
was successfully renatured after SDS-PAGE, while the bed
bug apyrase was resistant to denaturation by the 0.1%
trifluoroacetic acid and acetonitrile used for purification by
reverse-phase chromatography [9]. The wildtype human
enzyme has been reported to be stable for over 24 h at
37 -C in the presence of calcium, and for more than one
Figure 2. Multiple sequence alignment of three vertebrate and three blood-feeding arthropod CAN nucleotidase family members. The full-length
mouse, rat, and human protein sequences, along with three blood-feeding arthropod sequences (bed bug, and two different sand flies), were aligned using
the computer program CLUSTALW alignment algorithm, available through the Biology Workbench of the San Diego Supercomputer Center at http://
workbench.sdsc.edu/. Residues were shaded to indicate various levels of conservation using the BOXSHADE program, also available through the
Biology Workbench toolbox. Those amino acids that are strictly conserved among all family members are indicated by black shading. Those amino acids
that are similar at a given position are indicated by gray shading. The N-terminal RXR endoplasmic reticulum retention/retrieval motif of the vertebrate
sequences first described by Failer et al. [14] is represented by a black bar. The key residues for nucleotide and calcium binding (determined through
crystallography of the human CAN by Dai et al. [20]) are represented by pluses (+) and asterisks (*), respectively. The seven amino acids mutated by
Yang and Kirley [18] are represented by: Open circles ()) for those four mutations having very little activity remaining; filled circles (&) for those two
mutations having substantial residual activity; and a triangle (r) for the mutation (Glu to Tyr) which increased ADPase nucleotidase activity
approximately five-fold. The five point mutations that convert the wildtype human CAN into a 100 fold more potent ADPase capable of abolishing
platelet aggregation are shown as carets beneath the sequence (^). The accession numbers of the sequences used in this alignment are listed in the legend
to Figure 1.
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activity of this human CAN protein is retained for at least
six months when stored in buffer at 4-C under sterile
conditions (T.M. Smith, personal observations). Thus, the
human calcium activated nucleotidase is considerably more
stable than the naturally occurring soluble NTPDase
apyrases, NTPDase5 and NTPDase6 (T.L. Kirley, personal
observations). In fact, in stark contrast to the human CAN,
purified NTPDase5 (also known as CD39L4) was noted to
be unstable and prone to aggregation [19].
Mutagenesis and crystallographic analysis of the human
calcium activated nucleotidase
Extensive mutagenesis studies have recently been per-
formed on the human enzyme in an effort to evaluate key
amino acids in this family [18, 20]. Yang and Kirley [18]
used computational analysis of multiple sequence align-
ments of invertebrate and vertebrate members of the
apyrase family to identify eight highly conserved regions
of amino acids. The conserved regions were designated as
nucleotidase conserved regions 1Y8 (NCR 1Y8) and they
were used to direct a mutagenesis approach to identify
amino acids important for enzymatic function. Four amino
acids (Asp or Arg residues) contained in the NCRs were
mutated to alanine and, consistent with their degree of
conservation, all four mutations had substantial detrimental
effects on the enzyme activity. Several of these mutants
failed to bind the nucleotide analog Cibacron blue and
were sensitive to limited tryptic digestion, suggesting
alterations in their nucleotide binding pockets and/or their
ability to bind calcium and undergo the calcium-induced
conformational change. One mutation in the human
enzyme was reported (E130Y), which was targeted for
mutagenesis due to differences found between the sequen-
ces of the vertebrate and invertebrate sequences at that
residue (Figure 2). This E130Y mutation increased GDPase
activity two-fold and ADPase activity five-fold, which led
the authors to suggest that this amino acid was important
for determining the nucleotidase specificity for this family.
Interestingly, it was found that either CaCl2 or SrCl2
could induce the conformational change detected by the
increases in tryptophan fluorescence, confer resistance to
proteolysis, and provide thermal stability of the enzyme at
37 -C, although only calcium could support nucleotide
hydrolysis [18]. This suggested that calcium plays an im-
portant role not only as a nucleotide co-substrate, but also
for maintaining the conformation and structural stability of
the enzyme.
In addition to performing extensive mutagenesis studies
on the human protein, Dai et al. [20] reported the high-
resolution crystal structures of the enzyme both in the
presence and absence of the non-hydrolyzable GDP
substrate analog GMP-CP. The structures revealed a novel
nucleotide-binding motif comprising a five-blade beta
propeller structure, with a single calcium-binding site in
the middle of the central tunnel (Figure 3), coordinated
by Ser 100, Glu 147, Glu 216, Ser 277, and Glu 328 (num-
bering based on the soluble version of the apyrase minus
the signal peptide sequence). The single bound calcium
ion also contacts a water molecule and the carboxylate
group of Asp 101. With the exception of a conserved
glutamate substitution in the blood-feeding arthropod pro-
teins for Asp 101, the calcium binding residues are invariant
in all members (Figure 2). Consistent with this observation,
mutagenesis of these amino acids abolished the enzymatic
activity. The presence of the substrate analog GMP-CP
revealed that the guanine ring is bounded by Trp 165 and
Tyr 239. In addition, the phosphate recognition pocket is
lined mostly by hydrophilic residues, and site-directed
mutagenesis of these amino acids confirmed their roles in
the active site of the enzyme [20].
As mentioned earlier, the wild-type human enzyme is
very unlike the arthropod enzymes regarding its ability to
hydrolyze adenosine-based nucleotides, with the human
Figure 3. Structure of the human calcium activated nucleotidase in complex with the GMP-CP substrate analog. Ribbon diagrams of the human protein
b-propeller structure as viewed along (A) or perpendicular to (B) the central tunnel. The polypeptide is colored from blue at the C-terminus through to
red at the C-terminus. The structure reveals an unusual five-bladed b-propeller with five twisted b-sheets, each formed from four antiparallel b-strands.
The interface between neighboring blades is predominantly hydrophobic, with residues on the adjacent faces of the b-sheets in van der Waals contact.
The Ca
2+ ion (green sphere) is located at the middle of the central tunnel. The GMP-CP molecule is shown in a ball-and-stick representation (CPK color
scheme). The propeller has an approximate diameter of 44 A ˚ and height of 30 A ˚. The atomic coordinates are available at the Protein Data Bank (PDB
code 1S1D). Reprinted from Cell, Vol. 116, Dai et al., Structure and Protein Design of a Human Platelet Function Inhibitor, pp 649Y659, Copyright
(2004), with permission from Elsevier.
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tides. In addition, the human enzyme had no effect on an
in vitro assay of ADP-induced platelet aggregation, unlike
the invertebrate enzymes. Indeed, the tick apyrase has even
been reported to cause disaggregation and dispersal of
ADP-aggregated platelets [21]. The crystallographic data
of the human protein combined with sequence analyses of
the blood-feeding arthropod apyrases suggested that sub-
strate preference differences between the human and
arthropod family members resulted from divergence at
one or more of the non-conserved active site-residues.
Thus, in an effort to make the human enzyme more like the
blood-feeding arthropod counterparts with respect to
preferentially hydrolyzing ADP and inhibiting platelet
aggregation, Dai et al., 2004 [20] undertook a structure-
guided mutational analysis of the human enzyme to
identify and incorporate residues which contribute to
preference for ADP as substrate. 35 amino acid substitu-
tions were made, with a combination of five of those
mutations (see Figure 2) resulting in an engineered enzyme
that had a Ka for calcium activation of ADP hydrolysis in
the physiological range (dropping from 5.2 mM in the
wild-type to 1.6 mM in this multiple mutant), and a 100
fold higher rate of ADP hydrolysis. This engineered
G160S, L161S, K163M, T168K, E178M enzyme, desig-
nated HB (human/bedbug) apyrase, was also examined
with respect to its ability to inhibit ADP and collagen
mediated platelet aggregation. As shown by Dai et al. [20],
this guided mutational approach effectively converted the
enzyme to a form able to inhibit platelet aggregation,
similar to the blood-feeding arthropod apyrases (Figure 4).
Reversal of ADP-induced platelet aggregation was also
observed using the mutant HB enzyme. Thus, the func-
tional similarity of the vertebrate and invertebrate enzymes
is clearly demonstrated through the mutation of just a few
amino acids.
Therapeutic possibilities
The platelet is a major contributor to occlusive thrombus
formation in acute coronary syndromes and stroke in
humans, which are the primary causes of death and
disability in the industrialized world. The major platelet
inhibitors currently approved for use in thrombotic disor-
ders by definition target the platelet itself, with a
predominant side effect often being bleeding complications
(reviewed in [22Y24]). Achieving a potent anti-thrombotic
effect without undermining hemostasis would be a Fmagic
bullet_ against arterial thrombosis [24], thus new
approaches for anti-platelet therapy utilizing soluble
apyrases are being examined. One potential advantage of
Figure 4. Inhibition and reversal of ADP-induced platelet aggregation using wild-type and HB (human/bedbug) mutant CAN. Platelet aggregometry
and disaggregation studies were performed using human platelet-rich plasma treated with buffer (control), wild-type human CAN, or mutant G160S/
L161S/K163M/T168K/E178M (denoted HB CAN). (A) In the presence of buffer (control, blue line,0mg/ml) platelets are strongly aggregated in
response to ADP (10 mM final concentration added at 1 min, indicated by an arrowhead). HB CAN (blue traces) abrogates the ADP-induced platelet
aggregation in a concentration-dependent manner, with complete blockade of aggregation at 20 mg/ml enzyme. However, wild-type human CAN (red
trace) lacks the ability to prevent platelet aggregation even at a concentration of 400 mg/ml. (B) HB CAN was also tested for its ability to disrupt platelet
aggregates. Addition of 10 mM ADP (arrowhead) to platelet-rich human plasma resulted in maximal platelet aggregation within the first 4 min. HB CAN
was then added after induction of platelet aggregation by ADP at 3 min, and the resultant dissociation of the platelet aggregates was measured by the
decrease in optical density of the sample. The addition of increasing amounts of the HB CAN after initiation of platelet aggregation resulted in increasing
platelet disaggregation. Wild-type human CAN (red trace) lacks the ability to reverse platelet aggregation, even at a concentration of 400 mg/ml.
Reprinted from Cell, Vol. 116, Dai et al., Structure and Protein Design of a Human Platelet Function Inhibitor, pp 649Y659, Copyright (2004), with
permission from Elsevier.
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sine-based nucleotides is that they remove one of the major
factors of the platelet release reaction (ADP), effectively
limiting further platelet aggregation in a manner that does
not involve binding to the platelet surface or disruption of
intracellular protein machinery. Thus, serious bleeding
complications may be minimized using this approach. It
is important to point out however, that the vertebrate CAN
proteins described in this review are primarily UDP/GDP
hydrolyzing enzymes, with little endogenous ADPase
activity (hence, their physiological function likely does
not involve control of hemostasis). However, the blood-
feeding arthropod enzymes and also the HB mutant
constructed by Dai et al. [20] are potent ADPases, capable
of preventing ADP-mediated platelet aggregation.
There have been several recent reviews on the utilization
of ADP hydrolyzing enzymes (usually a soluble derivative
of the endothelial cell CD39/NTPDase1 apyrase, unrelated
to the calcium activated nucleotidase (CAN) family
members described in this report) in occlusive vascular
disorders [25Y30]. The therapeutic utility of these apyrases
has been demonstrated in a variety of cardio- and
cerebrovascular disorders, including middle cerebral artery
occlusion [31, 32], endothelial denudation-induced arterial
thrombosis [33], ATP and ischemia-induced norepineph-
rine release from heart synaptosomes [29], intestinal
ischemia-reperfusion injury [34], arterial balloon injury
[35], and cardiac xenograft transplantation [36, 37]. Hence,
the unique anti-platelet actions of the ADP hydrolyzing
enzymes make them particularly attractive as soluble
protein therapeutics for the inhibition of platelet-mediated
thrombotic pathologies.
Summary and conclusions
In this review, we have summarized the characterization of
a distinct new family of nucleotidases with representative
members found in both vertebrates and invertebrate blood-
feeding arthropods. Due to the strict dependency on
calcium reported for all characterized family members to
date, the designation CAN (calcium activated nucleotidase)
has been proposed for this family. Enzymatic studies of the
proteins isolated from different species have made it very
clear however that the invertebrate and vertebrate members
of this family do not share common nucleotide substrate
preferences, presumably related to their distinct physiolog-
ical functions. It is also interesting to note that the amino
acid sequences of this novel family of enzymes have no
homology to the NTPDase family of nucleotidases (e.g.,
CD39/NTPDase1) and their Fapyrase conserved regions_
(ACRs [15]). Thus, the CANs are enzymatically analogous,
rather than homologous in sequence, to the NTPDases,
performing similar enzymatic functions despite their
evolutionary distance. The differences in amino acid
sequences between these two families of nucleotidases
are also reflected in dramatic differences in their deter-
mined/predicted tertiary structures (see the article on
NTPDase3 mutagenesis and structure by Kirley et al.
appearing in this volume). Thus, we extend the observation
made by Valenzuela et al. [5], that the CAN and the
NTPDase families of nucleotide hydrolyzing enzymes are
the product of convergent evolution, having evolved
proteins of similar biochemical function from unrelated
genes, which give rise to unrelated 3-D protein structures.
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